a personalized mrna cancer vaccine, with keytruda, cut melanoma recurrence or death by 49% in a phase 2 trial with 152 patients. this is for high-risk melanoma after surgery. these early results show real potential to stop cancer from coming back or spreading.
A personalized mRNA cancer vaccine, developed by Moderna and MSD (Merck & Co.), significantly reduced the risk of melanoma recurrence or death when combined with Keytruda in a Phase 2 clinical trial.
